Drug Profile
SHP 656
Alternative Names: BAX 826; Bax-826; Polysialylated rFVIII; PSA-FVIII - Takeda/Xenetic Biosciences; PSA-rFVIII; SHP-826Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Baxter International; Xenetic Biosciences
- Developer Shire; Xenetic Biosciences
- Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
- Mechanism of Action Blood coagulation factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Haemophilia A
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 18 Jul 2017 Discontinued - Phase-II for Haemophilia A in Spain, Russia, Poland, Netherlands, Italy, Hungary, Germany, Bulgaria and United Kingdom due to lack of efficacy (Parenteral)
- 03 Apr 2017 Xenetic Biosciences plans a phase III trial for Haemophilia A